PGxAI Admitted to Creative Destruction Lab (CDL) Seattle — Computational Health 2025–2026

PALO ALTO, Calif., Sep. 22, 2025 — PGxAI has been admitted to the Creative Destruction Lab (CDL) Seattle program for the 2025–2026 cycle, joining the Computational Health stream hosted at the Foster School of Business, University of Washington. The objectives‑based CDL program pairs founders with experienced operators, scientists, and investors to set measurable milestones and accelerate commercialization.

About PGxAI PGxAI is an AI‑driven precision‑medicine company that transforms multi‑omics and clinical data into real‑time, gene‑guided prescribing support for health systems, payors, and life sciences partners.